Metabolic CRO Services
KCAS has a deep understanding of metabolic and endocrine diseases and the large molecule drugs used to treat them. From discovery through every phase of biologic development, KCAS offers comprehensive bioanalytical support for every stage of your metabolic drug development.
Rapid growth in metabolic treatments
A metabolite is the intermediate end product of metabolism. The term metabolite is usually restricted to small molecules. Metabolites have various functions, including fuel, structure, signalling, stimulatory and inhibitory effects on enzymes, catalytic activity of their own (usually as a cofactor to an enzyme), defence, and interactions with other organisms (e.g., pigments, odorants, and pheromones). A primary metabolite is directly involved in normal “growth”, development, and reproduction. KCAS has the experience to help with your metabolic project.
Metabolic therapeutics research, by leading scientists
KCAS offers a depth of knowledge in many therapeutic areas and the scientific acumen needed for successful drug programs. Our expertise in these areas of clinical research ensures that we move your molecule forward. As a full development program or a stand-alone service, we apply our expertise in therapeutic areas in clinical research to everything we do. We will help seamlessly transition your molecule through the phases of development in any of our therapeutic specialties, helping you get your drug to market faster.
We employ rigorous quality practices that go beyond our competition. Processes are continuously improved to ensure we consistently deliver a complete outsourcing experience to clients.
KCAS Bio provides high quality science and data services that have benefits for the entire drug development journey.
Agile, responsive, and easy to work with
We prepare and adapt our metabolic research based on a deep understanding of your drug development ambitions and wider business objectives.
KCAS Bio scientific insights
Blogs
A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions(1). With the development of innovative and personalized therapies, biomarker tracking is increasingly important to support the clinical development…
News
Dawn Dufield, PhD, Senior Director of Biopharmaceutical LC-MS/MS Services at KCAS, has been invited to lead a workshop discussion session on Lipidomics at an upcoming Gordon Research Conference from August 7-12 in Newry, ME. The event will be a week long conference highlighting recent developments in standardization, omics integration,…
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.